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Summary The role of human papillomavirus (HPV) detection in the management of patients with persistent
low-grade (mild dyskaryosis or less) cervical cytological abnormalities is unclear. We have analysed cytological
matenal from 167 such patients both cytologically and by non-isotopic in situ hybridisation (NISH) for HPV
16. 18. 31 and 33 and consensus primer polymerase chain reaction (PCR) amplification followed by both
generic and specific typing for these HPV types. Cervical intraepithelial neoplasia (CIN) 2 or 3 was present in
40 of 167 patients (23.9%), and the positive predictive values (PPVs) for the presence of CIN 2 or 3, of
moderate or severe dyskaryosis at repeat cytology and an HPV-positive NISH and genenrc PCR signal were
100%, 66% and 42% respectively. The corresponding sensitivities were 48%, 68% and 87%. Addition of
cytology to molecular analysis improved both PPV and sensitivity, the best combination being NISH and
cytopathology (PPV 71%, sensitivity 87%). These data demonstrate that the presence of CIN 2 or 3 in
patients with mild cytological abnormalities can be predicted by molecular detection of HPV in some cases,
particularly when combined with cytological analysis. However, the magnitude of this prediction is dependent
on the population of patients studied, and the clinical role of this approach therefore remains to be
defined.
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Human papillomaviruses are present in a wide variety of
intraepithelial lesions of squamous epithelium (de Villiers,
1989; Chang, 1990; Munoz et al., 1992; Schiffman. 1992),
including those of the cervix uteri. The presence of certain
HPV types (16, 18, 31, 33, 35 and others) is associated with
high-grade lesions namely CIN 2 and 3 and invasive cervical
carcinoma but these types are found less frequently in low-
grade lesions (CIN 1 and wart virus change only) and in
patients with negative cervical biopsies (Munoz et al., 1992;
Schiffman, 1992; Lorincz et al., 1993; Schiffman et al., 1993).
This association suggests that the detection of these viral
types in an individual patient might be predictive of the
presence of a high-grade lesion or a high-risk of progression
of a low-grade lesion. The morphology of signal produced by
in situ hybridisation correlates with the presence of viral
integration (Cooper et al., 1991a; Kristiansen et al., 1994),
and in studies of CIN and invasive carcinoma this punctate
pattern was found in all HPV-positive cervical carcinomas
and 69% of HPV-positive CIN 3 lesions (Cooper et al.,
1991b,c). Moreover, it has been suggested that it is not
merely the presence of high-risk HPV types but the amount
of viral DNA which is predictive of a high-grade lesion
(Cuzick et al., 1992), although the strength of this prediction
varies between studies (Cuzick et al., 1992, 1994; Herrington
et al., 1992a; Bavin et al., 1993).
The recommended management of patients with moderate-
ly and severely dyskaryotic cells present in a cervical smear is
immediate referral for colposcopy and possible treatment
(National Coordinating Network, 1992). The presence of
HPV DNA would therefore not influence management in
these patients. However, the management of patients with
persistent borderline or wart virus changes or mild dys-
karyosis is less clear as there are no cytopathological criteria
to distinguish between patients who will have a low- or
high-grade lesion on subsequent biopsy.
In this study, we have analysed the potential contribution
of HPV analysis in this situation by comparing the detection
of HPV DNA by PCR with the intrinsically less sensitive
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technique of in situ hybridisation and correlating these
molecular techniques with cytological and histological diag-
nosis.
Mateials and methods
Sanple collection andpreparation
Patients were selected on the basis of having been referred to
colposcopy for the investigation of persistent borderline or
wart virus change or mild dyskaryosis. Of the 167 patients,
99 were referred with a borderline smear, 39 with wart virus
changes and 29 with mild dyskaryosis. The current manage-
ment schedule for these abnormalities in this district is as
follows: borderline smears and those showing wart virus
changes only are repeated at 6-12 monthly intervals and
referral for colposcopy advised after three such abnormal
smears; mildly dyskaryotic smears are repeated at 6 monthly
intervals and referral for coloscopy advised after two or three
such abnormal smears. At colposcopy, two cervical smears
were taken with two separate Aylesbury spatulae and one
submitted for routine cytopathological diagnosis. The other
(sterile) was smeared in the conventional way for in situ
hybridisation and the spatula tip washed in sterile 0.9% (w/v)
sodium chloride to collect cells for PCR analysis. Cervical
smears were fixed in 70% ethanol, air dried and stored at
room temperature, and the cells in saline were pelleted by
centrifugation, digested with proteinase K (21Lgm.m-1) and
stored at -20°C according to the protocol of Bauer et al.
(1991, 1992). Any biopsies taken were processed in the
routine manner and haematoxylin and eosin-stained sections
examined. Standard cytopathological and histopathological
criteria were used for diagnosis (Coleman & Evans, 1988).
Non isotopic in situ hybridisation
This was carried out using a cocktail of digoxigenin-labelled
nick-translated probes for HPV 16, 18, 31 and 33 as des-
cribed previously (Hemrngton et al., 1992b). Smears of CaSki
cells, which contain integrated HPV 16 (Mincheva et al.,
1987), were used as positive controls. This procedure hasbeen shown previously to have a sensitivity of approximately
2.5-12 copies of integrated HPV per cell (Herrington et al.,
1991).
Polymerase chain reaction amplification and HPV typing
This was carried out by a modification of the method of
Bauer et al. (1991, 1992). Briefly, a 450 bp segment of the L1
gene was amplified using degenerate consensus primers. The
PCR products were dot blotted on to nitrocellulose and
hybridised with the following probes: mixed degenerate con-
sensus probes; PCR-generated 410 bp probes specific for
HPV 16, 18 and 31 individually; and biotinylated oligo-
nucleotide probes specific for HPV 6/11 and HPV 33. The
HPV 16, HPV 18 and HPV 31 degenerate probes were
generated by PCR using biotinylated dUTP and nested
primers and, when used together at low stringency, these
detect a wide range of HPV types (Bauer et al., 1992;
Schiffman et al., 1993). The probes were rendered HPV
specific by elevating washing stringency until only the appro-
priate plasmid-derived PCR product hybridised. Detection
was performed using streptavidin and biotinylated alkaline
phosphatase, with nitroblue tetrazolium, 5-bromo-4-chloro-3-
indolyl-phosphate as chromogen as previously described
(Chan et al., 1985). Plasmid-derived PCR products were
incorporated as positive controls and reactions carried out in
the absence of DNA as negative controls. The sensitivity of
this system was assessed by analysing dilutions of SiHa cells
(which contain 1-2 copies of HPV 16 per cell) diluted in a
constant background of 1 Lg ml-' (1 ng in each dot) carrier
sheared herring sperm DNA. A 236 bp P-globin fragment
was amplified in each case to assess DNA quality.
Results
Cytopathology andhistopatholog)
The cytopathological findings were as follows: two unsatis-
factory, 47 normal. 19 borderline, 62 wart virus infection, 18
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mild dyskaryosis, 11 moderate dyskaryosis and eight severe
dyskaryosis.
Biopsies were not taken in 25 cases and, of the remaining
142 cases, 14 were negative, 63 showed wart virus changes,
25 CIN 1, 12 CIN 2 and 28 CIN 3. No invasive carcinomas
were found. The correlation between colposcopic cytology
and histology is shown in Table I, and PPV ofmoderately or
severely dyskaryotic cytology for CIN 2 or 3 was 100% with
a sensitivity of 48% (see Table H1).
In situ hybridisation
A representative example of a NISH positive smear is shown
in Figure 1 and the correlation of NISH with biopsy histo-
logy in Figure 2. In situ hybridisation alone was positive in
41 cases (24.6%) and had a PPV of 66% for CIN 2 or 3 with
a sensitivity of 68% (Table II). The PPV of punctate signal
morphology was 80%, but the corresponding sensitivity only
30%.
Polymerase chain reaction
The procedure detected ten SiHa cells consistently and one
SiHa cell in approximately 50% of cases (in a DNA dilution
equivalent to 100 000 cells): this equates to a sensitivity of
1-10 copies of HPV per sample (data not shown). In six
cases no A-globin amplification occurred and hence the DNA
was not sufficient quality for HPV analysis: all of these cases
were HPV negative. Eighty-three cases (49.7%) were positive
after hybridisation with the generic HPV probe, giving a PPV
of 43% for CIN 2 or 3 and a sensitivity of 87% (see Table
II). If only cases typed for HPV 16, 18, 31 and 33 were
considered, the corresponding figures were 52% and 77%.
Exclusion of those cases in which no P-globin amplification
was obtained gave sensitivities of 92% and 81% for generic
and type-specific PCR (Figure 3) respectively. The combina-
tion of NISH and PCR improved sensitivity and PPV owing
to the detection of three further CIN 2 or 3 lesions by NISH:
in two of these, the absence ofP-globin amplification showed
Table I Correlation of cytology and histology of smears and biopsies taken at
colposcopy
WVI/Mild Moderate/severe
Histology Uns NAD Bord dyskaryosis dyskaryosis Total
No biopsy 0 15 3 6 0 25
Negative 1 7 1 5 0 14
WVI or CIN I 1 20 15 53 0 88
CIN 2 or 3 0 5 0 16 19 40
Total 2 47 19 80 19 167
Uns. unsatisfactory; NAD, no abnormality detected; Bord, borderline; WVI, wart virus
infection.
Table H Positive predictive values (PPVs) and sensitivities for the detection of CIN 2 or
3 by non-isotopic in situ hybridisation (NISH), generic and type-specific (TS) PCR,
cytology and combined analysis
PPV Sensitivity Relative risk (95% CI)
Cytology 100 48 7.0 (2.1-23.5)
Molecular analysis
NISH 66 68 6.4 (2.3-17.5)
Punctate signal 80 30 4.3 (2.4-7.7)
Generic PCR 42 87 7.1 (3.2-15.8)
TS PCR 52 77 6.1 (2.6-14.4)
NISH and genenrc PCR 44 95 17.9 (4.5-70.3)
NISH and TS PCR 54 90 13.4 (3.2-57.1)
Molecular analysis and cytology
NISH and cytology 71 87 16.8 (2.3-122.3)
Punctate signal and cytology 89 62 8.3 (2.0-34.0)
Generic PCR and cytology 43 92 11.6 (3.9-34.7)
TS PCR and cytology 55 87 11.3 (3.0-43.0)
NISH, generic PCR and cytology 45 97 35.9 (6.1-211.7)
NISH, TS PCR and cytology 56 97 54.0 (4.6-636.1)HPVam*m and prodk ofamp diglade CIN
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Figue 1 A cervical smear hybridised with a cocktail of HPV
probes for HPV 16, 18, 31 and 33. Note the presence of both
diffuse and punctate signal within epithelial cell nuclei.
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Figue 2 Relationship between NISH analysis of cervical smears
and biopsy histology.
that the DNA was not of sufficient quality for PCR. The
correlation of PCR with biopsy histology is shown in Figure
4 and the spectrum of HPV types identified in Figure 5.
Cytology and NISHIPCR
Those cases containing HPV types other than HPV 6/11 as
determined by molecular means were combined with those
detected by cytology. The PPV of cytology and NISH for
CIN 2 or 3 was 71% and the sensitivity 87%. Analysis of
NISH signal morphology gave a PPV of 89% and sensitivity
of 62%. The corresponding figures for generic PCR and
cytology were 43% and 92%. The combination of all three
techniques unproved sensitivity still further to 97%, with
only a single patient with CIN 2 remaining undetected: how-
ever, the PPV was still 45-56% (see Table II).
Discusso
Molecular analysis of HPV DNA in patients with minor
cytological abnormalities has been advocated to identify cur-
rent high-grade lesions underdiagnosed by cytology (Cuzick
et al., 1992; Bavin et al., 1993), and it has been suggested
that high copy number infection with these viruses is more
predictive than the detection of viral presence alone (Cuzick
et al., 1992; Hernngton et al., 1992a; Bavin et al., 1993).
In this study, cytological assessment and molecular HPV
typing were carried out on samples taken at the same colpo-
scopic examination to minimise sampling error. Non-isotopic
in situ hybridisation (NISH) alone detected 68% of the CIN
2 or 3 lesions but was also positive in 11% of smears from
patients without such lesions, giving a positive predictive
value (PPV) of 66%. The presence of punctate signal, which
correlates with viral integration (Cooper, 1991a), was predic-
tive of a high-grade lesion (PPV 80%) but insensitive (sensi-
tivity 30%). Generic PCR amplification of HPV had high
sensitivity (87%) but low predictive value (42%) and, if only
Figue 3 PCR products generated by amplification of cervical
smears using consensus primers and hybridised with an HPV
16-specific PCR-generated probe. Each well represents a separate
case and the HPV plasmids row contains products derived from
plasmid DNA from HPV types 6, 11. 16. 18, 31. 33 and 35. The
well in column 8 of this row contains the product ofamplification
in the absence of DNA. Cases Al. A2. A8. B8 and Cl contain
HPV 16 sequences.
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Figure 4 Relationship between biopsy histology and both
generic () and type-specific (0) PCR. The cases in which
P-globin amplification was negative. and HPV 6 11-positive cases
(see Figure 5) have been excluded.
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Fge 5 Type-specific PCR and histological diagnosis. In two
caces (one of CIN I and the other CIN 3). both HPV types 16
and 31 were present. -, HPV 16; =i. HPV 18; F. HPV
31; [] HPV 33; M, HPV 6/11; M. untyped HPV.
those cases typed specifically as HPV 16, 18, 31 and 33 were
considered, the predictive value improved (52%) but the
sensitivity dropped to 77%. Moreover, high-risk HPV types
were present in smears from patients with low-grade lesions.
Similarly, untyped viral sequences were associated not only
with low-grade lesions and normal biopsies, but also with
four cases of CIN 2 or 3: in two of these, NISH was positive,
indicating the presence of sequences related to the high-risk
HPV types present in the NISH cocktail (HPV 16, 18, 31 and
33) (Herrington et al., 1993). Combination of NISH and
PCR detection of HPV improved sensitivity (to 95%), but
the PPV was still low (44%) owing to PCR positive smears
from patients without high-grade lesions.
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There is therefore an inverse relationship between the
sensitivity and PPV of HPV DNA detection for current
high-grade CIN. The greater prediction of NISH, which is
intrinsically less sensitive than PCR, confirms the association
described by Cuzick et al. (1992), but molecular detection
alone using the techniques described here is not applicable to
routine clinical testing in this population.
The combination of cytology with molecular detection of
HPV is logical as not all CIN 2 and 3 lesions are HPV
positive, whether assessed by NISH or PCR (Cooper et al.,
1991b; Munoz et al., 1992; Troncone et al., 1992; Walboomers
et al., 1992). Addition of cytology to NISH increased both
sensitivity and PPV, to 87% and 71% respectively. Combina-
tion of cytology and PCR was more sensitive and predictive
than PCR alone but less predictive than the combination of
NISH and cytology. If all three techniques were used, very
high sensitivity was achieved (97%), with only one case of
CIN 2 remaining undetected. However, the PPV was still
low, again because of the number of PCR-positive cases.
Overall, therefore, the best combination of PPV and sen-
sitivity was achieved by combining NISH and cytology.
However, accurate definition of the patients analysed is
important as the predictive value is sensitive to the case mix
under study. If a greater proportion of lesions is high grade,
as was the case in one previously reported study (Cuzick et
al.. 1992), the test will appear more predictive, given the
same sensitivity. Indeed, good prediction can be achieved
either by reducing the sensitivity of a test for low-grade
lesions, i.e. by increasing its discrimination between low- and
high-grade lesions, or by increasing the proportion of high-
grade lesions in the population being studied. In patients
with low-grade cervical cytological abnormalities, this pro-
portion is likely to be small and good prediction will be
reliant on the discriminative power of the test. Clinical utility
will therefore require a test which is both discriminative and
sensitive. This has yet to be achieved with current metho-
dology, and the data presented here show that NISH analysis
in unlikely to provide the degree of discrimination required,
as productive viral infection is present in a proportion of
patients who do not have CIN 2 or 3: this caveat is also
likely to apply to semiquantitative PCR techniques.
Although HPV analysis is only moderately predictive of a
current high-grade lesion, those patients who are HPV
positive and have a low-grade lesion may be at greater risk of
progression to a high-grade lesion with time. If this were the
case, population selection would be less problematic as a link
between HPV positivity and progression would negate the
biasing effect of case mix. Prospective follow-up studies of
HPV analysis are needed to address this question.
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